The Oncology Institute, Inc. TOI Deferred acquisition and contingent consideration
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept toi:BusinessCombinationConsiderationTransferredOtherCurrent.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s deferred acquisition and contingent consideration.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s deferred acquisition and contingent consideration?
- The Oncology Institute, Inc. (TOI) reported deferred acquisition and contingent consideration of $125K in Q1 2026.
- How has The Oncology Institute, Inc.'s deferred acquisition and contingent consideration changed year-over-year?
- The Oncology Institute, Inc.'s deferred acquisition and contingent consideration decreased by 12.6% year-over-year, from $143K to $125K.
- What is the long-term trend for The Oncology Institute, Inc.'s deferred acquisition and contingent consideration?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s deferred acquisition and contingent consideration has grown at a -52.0% compound annual growth rate (CAGR), from $2.36M to $125K.